Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
MannKind Corporation
Type
Public company
Traded as NASDAQ: MNKD
Industry Biotechnology
Founded 1991
Founder Alfred E. Mann
Headquarters Westlake Village, CA, United States
Number of employees
250
Website www.mannkindcorp.com

MannKind Corporation, based in Westlake Village, California, is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and Pulmonary Arterial Hypertension (PAH). The company, while founded in February 1991, took its present form in 2003 as a merger of three companies owned by Alfred E. Mann, Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp which was developing a novel allergy vaccine technology. MannKind Corporation was named after its founder, Alfred Mann, who invested at least $900 million of his own fortune in the firm. One of the former companies, Pharmaceutical Discovery, was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone Inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.

In November 2015, Hakan Edstrom stepped down as CEO and president and will remain until July, 2017 to provide other services for the company. Company founder Alfred Mann stepped in as interim CEO. 8-K file on November 19, 2015. In May 2017, Michael Castagna was named CEO of MannKind Corporation.

MannKind's corporate headquarters are in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut.

Afrezza is an ultra-rapid-acting insulin peaking 12 to 15 minutes following inhalation and exits your body within 2-3 hours. The FDA approved Afrezza on June 27, 2014 with a 13-1 vote for type 1 diabetes and 14-0 vote for type 2 diabetes.

On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi.

The firm has stated that it is developing a next generation inhalation technology, a miniature, breath-powered inhaler used in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving technosphere formulations of different therapeutic proteins.

Investment goal date:
Dividends reinvested
MannKind Corporation MNKD report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-08
--
--
Q4 2017
2018-03-16
--
--
Q4 2017
2018-03-09
--
--
Q3 2017
2017-11-09
--
--
Q3 2017
2017-11-07
-0.3100
0.0000
Q2 2017
2017-08-07
-0.3500
-0.3500
Q1 2017
2017-05-10
-0.1700
-0.1700
Q4 2016
2017-03-16
0.5600
0.5500
Q3 2016
2016-11-09
1.3000
1.3000
Q2 2016
2016-08-08
-0.3500
-0.3500
Q1 2016
2016-05-09
-0.3000
-0.3000
Q4 2015
2016-03-14
-0.8500
-3.3000
Q3 2015
2015-11-09
-0.4000
-0.4000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
AYM CAPITAL, LLC
1443400
BlackRock Fund Advisors
10319727
BlackRock Inc.
3743311
BlackRock Institutional Trust Company, N.A.
7023580
BlackRock Investment Management, LLC
1258403
D. E. Shaw & Co., Inc.
936988
EQUITEC PROPRIETARY MARKETS, LLC
503500
GOLDMAN SACHS GROUP INC
3664405
GSA CAPITAL PARTNERS LLP
691920
JACOBS LEVY EQUITY MANAGEMENT, INC
554031
MORGAN STANLEY
544145
NORTHERN TRUST CORP
776899
SCOPIA FUND MANAGEMENT, LLC
982930
STATE STREET CORP
1028950
Vanguard Group, Inc
2967938
Major Shareholders
Name Relationship
Total Shares
Holding stocks
MANN ALFRED E
0.2500% (1005990)
MNKD /
PFEFFER MATTHEW J
0.0200% (81961)
DSKX / MNKD /
KRESA KENT
0.0600% (237589)
FLR / MNKD /
NORDHOFF HENRY L
0.0200% (88745)
BTX / MNKD /
CONSIGLIO RONALD J
0.0200% (98422)
MNKD /
COHEN ABRAHAM E
0.0100% (56424)
BTX / MNKD /
Edstrom Hakan
0.2800% (1114340)
MNKD /
Thomson David
0.0100% (34067)
MNKD /
Friedman Michael A
0.0100% (47500)
CELG / MNKD /
MacCallum David
0.0200% (100109)
MNKD /
Palumbo Diane
0.0100% (50624)
MNKD /
Martens Juergen
0.0300% (106539)
MNKD / NEOS /
Tross Stuart A
0.0200% (100000)
AMGN / MNKD /
Adreveno Linda A
0.0200% (92200)
MNKD /
Kocinsky Joseph
0.0100% (23010)
MNKD /
Alinaya Rosabel Realica
0.0100% (29543)
MNKD /
% ()